Researchers at the Children's Cancer Institute, Australia, have discovered that the AlyREF, a cellular protein plays a crucial role in the pathophysiology of neuroblastoma by enhancing the cancer-driving activity of MYCN protein. This discovery is crucial, as earlier studies have demonstrated that children with neuroblastoma with high levels of MYCN protein in cancer cells lead to a much poorer prognosis. This made researchers focus on MYCN protein as a target for therapy, but it was not a suitable target for drug design due to multiple transactivation target genes, which are regulated by multiple protein-protein and protein-DNA interactions.
Scientists planned to search for similar pathways and molecules that work closely with MYCN protein. This research helped identify an association of MYCN with ALYREF to drive the growth of neuroblastoma cells. It is observed that the binding of…
